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INTRODUCTION
DNA double-strand breaks (DNA DSB) are highly deleterious and their formation is a major determinant of the cytotoxicity of radiation therapy and several widely used anticancer chemotherapeutic agents (1) . An early event following the formation of DSBs is the phosphorylation of the X isoform of histone H2A at serine-139 by the PI3-like kinases (DNA-PKcs, ATM and ATR), resulting in γH2AX (1, 2) . Many hundreds of copies of γH2AX form foci at DSB sites. We previously identified γH2AX as an attractive target for molecular imaging and quantification of DSBs in vivo (3) . This exclusively nuclear protein can be targeted using anti-γH2AX antibodies, conjugated to the cell-penetrating peptide (CPP), TAT, which also harbours a nuclear localization sequence (NLS), to allow cellular internalization and nuclear translocation. Anti-γH2AX-TAT was then conjugated to fluorophores or the radionuclide 111 In, to allow fluorescence microscopy or SPECT imaging, respectively.
Apart from being a target for imaging DSBs, we have shown that γH2AX is also a good target for Auger electron radiotherapy (4) . Auger electrons are low energy electrons (1-10 eV) with very limited track length (in the nm-μm range) that, when emitted in close proximity of DNA, are highly damaging (5) . When anti-γH2AX-TAT was radiolabeled with the Auger electron-emitter, 111 In, at high specific activity (SA), it caused amplification of DNA damage induced by chemotherapy and IR, reduction of clonogenic survival in vitro, and inhibition of tumor growth in vivo. However, none of the constituent moieties of anti-γH2AX-TAT ensure the conjugate's tumor-specific uptake, and any non-specific internalization in normal cells would be undesirable as it may cause toxicity.
Here, we report on two 111 In-labeled radioimmunoconjugates that target not only γH2AX but also, through the incorporation of the epidermal growth factor (EGF) peptide, the EGF receptor (EGFR) which is frequently overexpressed in cancer e.g. MDA-MB-468
human breast cancer cells express 1.3 × 10 6 EGFR/cell (6) , but is expressed to a much lower extent in normal tissues e.g. normal hepatocytes express 8 × 10 4 to 3 × 10 5 EGFR/cell (7).
These dual-specific immunoconjugates incorporate the nuclear localization sequence (NLS)
of SV-40 large T-antigen, to promote nuclear accumulation of the γH2AX-seeking moiety.
Two different synthetic strategies were pursued. First, EGF conjugated to NLS was covalently bound to anti-γH2AX antibody via a non-cleavable poly-ethylene glycol (PEG 6 ) linker. Additionally, EGF was linked to NLS-conjugated anti-γH2AX antibody via a cleavable disulphide bond (8) . We report on the in vitro and in vivo characteristics of both compounds, and demonstrate the potential of the 111 In-labeled cleavable compound as an
Auger electron therapeutic radiopharmaceutical. Toronto, ON) (9) . These cells were tested and authenticated by the provider, using short tandem repeat profiling. The length of time in culture of these cells was less than 6 months after retrieval from liquid nitrogen storage. The number of EGFR/cell for MDA-MB-468 and 231-H2N cells is 1.3 x 10 6 and 2 x 10 5 , respectively (10) . Cells were cultured in 5% CO 2 
MATERIALS AND METHODS
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Synthesis of Non-Cleavable Immunoconjugates
A schematic overview of the synthesis of non-cleavable immunoconjugates is shown in Supplementary Figure 1A . A full description of the synthesis is available in the Supplementary Methods. Anti-γH2AX antibody or non-specific IgGs from rabbit serum was conjugated to benzyl-DTPA (BnDTPA) to allow 111 In labeling, or to Cy3 or AlexaFluor555 (AF555) to allow fluorescence microscopy. This was reacted with (SM(PEO) 6 ), yielding maleimide-activated conjugates, BnDTPA-anti-γH2AX-(PEO) 6 -mal or BnDTPA-rIgG-(PEO) 6 -mal. Epidermal growth factor (EGF) was conjugated to the NLS-peptide, GGPKKKRKVGYGCG, using EDC/NHS chemistry, yielding EGF-NLS. EGF-NLS was conjugated to BnDTPA-anti-γH2AX-(PEO) 6 -mal or BnDTPA-rIgG-(PEO) 6 -mal. The size of BnDTPA-anti-γH2AX-PEO 6 -NLS-EGF was determined using polyacrylamide gel electrophoresis (PAGE) electrophoresis followed by Coomassie staining. 111 In-labeling was achieved by addition of 111 In-chloride ( 111 InCl 3 ; Perkin Elmer, Boston, MA). For brevity and because BnDTPA was used as the radiometal chelator for all radioimmunoconjugates reported here, BnDTPA-anti-γH2AX-PEO 6 -NLS-EGF and BnDTPA-rIgG-PEO 6 -NLS-EGF are referred to hereafter as anti-γH2AX-PNE and rIgG-PNE, respectively.
Synthesis of Cleavable Immunoconjugates
A schematic overview of the synthesis of cleavable immunoconjugates is shown in Supplementary Figure 1B . A full description of the synthesis is available in the Supplementary Methods. Anti-γH2AX antibody or non-specific IgGs from rabbit serum was conjugated to BnDTPA to allow 111 In labeling, or to Cy3 or AlexaFluor555 (AF555) to allow 6 fluorescence microscopy. This was reacted with SANH for addition of a hydrazine moiety, and subsequently with an N-terminal serine-containing NLS-peptide (SGGPKKKRKVGYGCG) and sodium periodate. EGF was modified with a disulphide function using SMPT. EGF-SMPT was added to BnDTPA-or fluorophore-tagged IgG-NLS, yielding BnDTPA-anti-γH2AX-NLS-SS-EGF and BnDTPA-rIgG-NLS-SS-EGF (referred to hereafter as anti-γH2AX-N-SS-E and rIgG-N-SS-E). 111 In-labeling and determination of radiolabeling yield was achieved as described above. The size of BnDTPA-anti-γH2AX-NLS-SS-EGF was determined using PAGE electrophoresis followed by Coomassie staining.
To study the influence of the NLS sequence, the same conjugate was prepared using a disrupted NLS sequence (dNLS, SGGPGGKRKVGYGCG), denoted as 111 In-anti-γH2AX-dN-SS-EGF.
Competition Binding Assay
EGFR-and γH2AX-binding by anti-γH2AX-PNE and anti-γH2AX-N-SS-E were compared to that of unmodified EGF or anti-γH2AX antibody in competition assays against 123 I-EGF or 123 I-labeled anti-γH2AX antibody as previously described (10) . 123 I-labeling of EGF (Peprotech, London, UK) and anti-γH2AX antibody (Merck, Nottingham, UK) was achieved using the Iodogen method (11) . This method is available in the Supplementary information.
Cleavage of Disulphide Linker
To determine whether the disulphide linker was cleavable under reducing conditions, a cell-free assay was performed using glutathione as the reducing agent. rIgG-N-SS-E was synthesized, as described above, using 123 I-EGF in place of EGF, to yield rIgG-N-SS-*E.
SEC was performed on IgG-N-SS-*E using a G50 sephadex mini-column, and the amount of 
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123 I in serial fractions was measured in an automated gammacounter. IgG-N-SS-*E was exposed to 1 mM glutathione for 2 h at room temperature, and SEC performed using a G50 sephadex minicolumn. In-rIgG-N-SS-E (0-6 MBq/μg) either alone or in combination with IR. The highest concentration used, 0.25 µg/mL, can be easily achieved in vivo by injection of a 20 g mouse with 10 µg of conjugate.
Confocal Microscopy
231
After incubation at 37°C for 24 h, 2 x 10 3 cells were seeded per well in triplicate on a 6-well plate, and incubated with fresh growth medium (2 mL). After 7-14 days, plates were washed with PBS and cell colonies were stained with methylene blue (2% methylene blue in water:methanol 1:1), and counted using a Gelcount automated plate reader (Oxford Optronics, Oxford, UK).
Biodistribution
All animal procedures were carried out in accordance with the UK Animals In-anti-γH2AX-N-SS-E, tumor sections were stained for γH2AX as before (3), using an antibody raised in mouse and an AlexaFluor488-conjugated goat anti-mouse secondary antibody. An AlexaFluor555-conjugated goat anti-rabbit antibody was used to stain the IgG moiety of 111 In-anti-γH2AX-N-SS-E. In some cases, a 100-fold excess of EGF was co-injected to block EGFR. For SPECT imaging, mice were anesthetized using isoflurane at 24 h p.i. and SPECT-CT images were acquired using a nanoSPECT-CT scanner (Bioscan, Washington DC, USA). Volume of interest (VOI) analysis on SPECT images was performed using the Inveon Research
Workplace software package (Siemens, Camberley, UK).
on June 
Statistical Analysis
All statistical analyses and non-linear regression was performed using Graphpad Prism (Graphpad Software Inc). 1-way or 2-way ANOVA was used for multiple comparisons. The F-test was used to compare parameters between curves.
RESULTS
Synthesis, Affinity and Cleavage
Two radioimmunoconjugates were synthesized, based on anti-γH2AX antibodies and EGF. The linkage between the antibody and EGF moieties was made either using a noncleavable PEG linkage, or using a cleavable disulfide bond. All compounds were synthesized so that they contained, on average, a 1:1 ratio of the various moieties. Radiolabeling yield for 111 In labeling was >95%. The affinity for EGFR of EGF-containing conjugates was compared to that of 123 I-EGF. Similarly, the affinity of anti-γH2AX-containing conjugates was 
Cytotoxicity of Radioimmunoconjugates
In clonogenic survival assays the surviving fraction (SF) of MDA-MB-468 cells was reduced to 52 ± 1.3% following exposure to IR (4 Gy) alone (P < 0.0001) (Figure 4) . Unlabeled, non-cleavable immunoconjugate, anti-γH2AX-PNE, was not itself cytotoxic and did not significantly enhance the cytotoxic effect of IR (P > 0.05). Radiolabeled noncleavable immunoconjugate, 111 In-anti-γH2AX-PNE, reduced SF to 62 ± 4% and showed an additive effect in combination with IR when SF was reduced to 41 ± 3% (P < 0.05).
Increasing the concentration of 111
In-rIgG-N-SS-E or 111 In-anti-γH2AX-N-SS-E had no effect on the SF of sham-irradiated 231-H2N cells ( Figure 4A ). Similarly, 111 In-rIgG-N-SS-E had no effect on SF in irradiated cells. However, the addition of 111 In-anti-γH2AX-N-SS-E did enhance the cytotoxicity of IR, although only at the highest concentration tested (50% at 0 μg/mL versus 31% at 0.5 μg/mL; P < 0.01). As for 231-H2N cells, 111 In-rIgG-N-SS-E did not affect survival in MDA-MB-468 cells ( Figure 4A ). In contrast, in irradiated MDA-MB-468 cells, 111 In-anti-γH2AX-N-SS-E reduced the clonogenic survival in a dosedependent manner across the range of concentrations tested (75% at 0 μg/mL versus 19% at 0.25 μg/mL; Spearman P-value = 0.0028; P<0.001), whereas 111 In-anti-γH2AX-N-SS-E caused a less marked but statistically significant reduction in SF in sham-irradiated cells (100% at 0 μg/mL vs. 67% at 0.25 μg/mL; P < 0.001) ( Figure 4B ).
Increasing the specific activity (SA) of In-anti-γH2AX-N-SS-E to block EGFR, uptake in irradiated xenografts decreased to 1.07 ± 0.14 %ID/g (P<0.001). γH2AX staining of sections of tumor, taken from mice after 10
Gy irradiation, showed marked induction of γH2AX foci (9.8 ± 0.4 foci/cell), even at 24 h after irradiation, compared to sham-irradiated tumors (2.2 ± 0.3 foci/cell) ( Figure 5B ). To demonstrate γH2AX targeting, tumor sections were stained for γH2AX and anti-γH2AX-N-SS-E ( Figure 5C ). Some degree of non-specific background staining of anti-γH2AX-N-SS-E was observed, but anti-γH2AX-N-SS-E colocalized with every γH2AX focus.
Taken together, these results demonstrate that 111 In-anti-γH2AX-N-SS-E uptake in tumors is dependent on γH2AX expression, anti-γH2AX/γH2AX interaction and EGF/EGFR In-anti-γH2AX-N-SS-E was relatively low (4.67 ± 1.29 %ID/g and 9.00 ± 1.02 %ID/g at 24 h p.i., respectively). There was no significant difference in liver and kidney uptake whether 111 In-anti-γH2AX-N-SS-E or 111 In-rIgG-N-SS-E was administered. Liver and kidney uptake was similar in irradiated and control mice for both tracers (P > 0.05).
DISCUSSION
Radionuclides that emit Auger electrons are of interest as therapeutic agents, due to the high linear energy transfer (LET) and short range in tissue of these particles. Since ionizations are clustered within several cubic nanometres around the point of decay of Auger electron-emitting radionuclides, leading to local absorbed radiation doses in excess of 100
Gy, their targeted delivery to the DNA of cancer cells holds promise as a therapeutic strategy in cancer (14, 15) . We have previously shown that the combination of IR and γH2AX
targeted Auger electron exposure is a very effective tumor control measure in vitro as well as in vivo (3, 4, 15) . Here, our aim was to increase tumor selectivity of a γH2AX-targeting
Auger electron-emitting compound by adding an EGF moiety.
Using a synthetic strategy similar to one we have employed in the past to target the cyclin-dependent kinase inhibitor protein, p27 kip1 (10) , EGF was tagged with NLS and covalently linked to an anti-γH2AX antibody via a non-cleavable PEO 6 linker to generate 111 In-anti-γH2AX-PNE (Supplementary Figure S1A) . conjugate did not co-localize with IR-induced γH2AX foci in cells ( Figure 2B ). The most likely explanation for this observation is that the concentration of AF555-anti-γH2AX-PNE in the nucleus was too low to generate a detectable signal. Therefore, the immunoconjugate was re-designed to allow improved DNA-targeting after internalization. A conjugate was synthesized with the EGF and γH2AX-NLS sections separated by a disulphide bond (Supplementary Figure 1B) . Disulphide bonds have been used extensively in antibody-drug conjugate (ADC) design, to enable delivery of drugs to cells through linkage to antibody vectors (16) . Upon internalization of this conjugate, the disulphide bridge is cleaved through the action of reductive intracellular thiols such as glutathione (8) . We have shown that this approach can be used for the release of the DNA- MDA-MB-231) that express NK1R, the receptor for substance P (18).
Several endogenous compounds and enzymes play a role in the cleavage of disulfide bonds in endosomes and lysosomes (19) . Of these, glutathione and cysteine constitute the major physiological thiols responsible for the intracellular reducing environment, with glutathione being the most prevalent cellular thiol accounting for >90% of the total nonprotein sulfur (20) . Another mechanism of endosomal disulfide bond cleavage is the activity of the enzyme, GILT (γ-interferon-inducible lysosomal thiol reductase). One study used folate conjugated to a BODIPY fluorescent probe, conjugated to a rhodamine fluorescent 
probe through a reducible disulfide linkage. It was shown that the disulfide bond was reduced very efficiently throughout the entire intracellular folate trafficking process (21) . Here, we chose to demonstrate disulfide bond cleavage using glutathione since it is the most prevalent intracellular reductive agent. Taken together, reductive cleavage of disulfide linkers is a process that has been observed in the endosomes and cytosol of many different cells, and, as here, provides an excellent mechanism to deliver nuclear targeting radiopharmaceuticals to cancer cells. Figure 2A) and to internalize into cells in an EGF/EGFR dependent manner ( Figure 2 ). In confocal microscopy experiments, AF555 signal was clearly seen in the nuclei of irradiated cells that expressed abundant γH2AX, suggesting that cleavage at the disulfide bond of AF555-anti-γH2AX-N-SS-E had occurred, with release and translocation to the nucleus of AF555-anti-γH2AX-NLS ( Figure 2B, Figure 3A) . This process, which would be expected to be similar for (23, 24) . Then, the NLS tag interacts with importins so that anti-γH2AX-NLS is transported into the nucleus, where it binds to IR-induced γH2AX, expressed in foci at the sites of DSBs.
Anti-γH2AX-N-SS-E functions as intended, as it was shown to bind to EGFR (Supplementary
The release of 111 In-anti-γH2AX-NLS from the delivery-moiety, EGF, led to marked nuclear accumulation of 111 In in irradiated cells with induced γH2AX expression ( Figure 3A) , and localization at DSB sites (Figure 2A ). Importantly, it was shown that increased intranuclear accumulation of
111
In was not the consequence of increased cellular uptake of the compound due to EGFR copy number modulation, which remained unchanged after irradiation, under the experimental conditions used (see Supplementary Figure S6 ). The In-DTPA-EGF is that the former has a defined intranuclear DNAassociated target, whereas the latter does not, so relies on nuclear accumulation due to EGFR NLS. A similar mechanism accounts for the radiotoxicity of the 125 I-labeled anti-EGFR mAb 425 antibody (30) or 125 I-m225 (31) . Although several studies show that even 125 I-labeled non-internalizing antibodies can have potent cytotoxic effects (31), the recently described 111 In-labeled anti-EGFR antibody, nimotuzomab, which is in itself a cytotoxic agent, conjugated to a nuclear localization sequence, demonstrates very elegantly that conjugation of a nuclear localization sequence to the anti-EGFR antibody results in increased nuclear uptake, and therefore leads to increased radiotoxicity (32) . One could hypothesize that all of these agents could be further improved if a DNA-targeting moiety were to be added.
In vivo biodistribution studies confirm that 111 In-anti-γH2AX-N-SS-E uptake in EGFR-expressing MDA-MB-468 xenograft tumors is dependent on γH2AX expression, anti-γH2AX/γH2AX interaction and EGF/EGFR binding ( Figure 5A ,B), and that anti-γH2AX-N-SS-E targets γH2AX in irradiated tumor tissue in vivo ( Figure 5C ). Taken together, the results reported in this paper show the EGFR-specific, tumor-specific delivery of a γH2AX-targeting radiopharmaceutical for Auger electron therapy, and encourage further investigation of this type of bispecific conjugate.
CONCLUSION
The cleavable radiolabeled immunoconjugate, 111 In-anti-γH2AX-N-SS-E, binds to 
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